Pulsenmore Ltd Dossier - Source-backed chat

Pulsenmore Ltd

PLSMNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.60

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.17Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $14.1M

Shares Outstanding 6.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Pulsenmore Ltd. is a pioneer in home-use prenatal ultrasound technology, having achieved a major milestone with its Nasdaq listing in January 2026 and securing FDA authorization for its Pulsenmore ES system. While the company's FY 2025 revenue surged 374% to $12.5 million, this was heavily driven by a one-time $9.6 million settlement with GE Precision Healthcare, which also terminated their commercial component agreement. Excluding this settlement, underlying revenues remain small, and the company continues to be loss-making (reporting a net loss of $5 million in FY 2025). Pulsenmore is actively expanding its footprint in the U.S. through strategic partnerships with Ouma Health and specialized clinics, and recently secured $7.5 million in a private placement. However, given its high concentration of revenue in Israel, dependence on additional capital, and early stage of U.S. commercialization, a Hold recommendation is warranted until sustainable recurring revenue streams are established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets0 analysts

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

Slower-than-expected clinical adoption of home-use ultrasounds in the U.S. due to regulatory, reimbursement, or workflow integration hurdles. The loss of the GE HealthCare partnership limits global distribution scale, forcing the company to burn through its cash reserves and execute highly dilutive capital raises.

Base CaseCentral scenario

$4.5050%

Steady but gradual commercial rollout in the United States. The company utilizes its $21.7 million in liquid assets and the $7.5 million private placement to build out U.S. infrastructure. Revenue grows moderately as clinical workflows adapt to remote prenatal monitoring, but the company remains loss-making in the near term due to high R&D and marketing expenses.

Bull CaseUpside scenario

$8.0030%

Rapid adoption of the Pulsenmore ES system across the U.S. healthcare system driven by partnerships with virtual maternity care providers like Ouma Health and leading maternal-fetal medicine clinics. Successful integration of AI capabilities through the Israel Innovation Authority's $1 million program enhances product value, leading to high-margin recurring software-as-a-service (SaaS) revenues and accelerated path to profitability.

Scenarios reflect our research view at the research date.

Key Investment Merits

First and only FDA-authorized home-use prenatal ultrasound system, establishing a strong first-mover advantage in the U.S. remote diagnostics market.
Strategic partnerships established with virtual maternity care platforms (Ouma Health) and specialized clinics (TLC Perinatal, CFFM) to validate clinical workflows.
Selection for a $1 million AI development project by the Israel Innovation Authority, supporting the integration of advanced technology into remote care.
Improved balance sheet liquidity following a $7.5 million private placement in June 2026.

Key Investment Risks

High concentration of historical revenue in Israel, primarily with a single customer (Clalit Health Services).
Termination of the commercial partnership and component agreement with GE Precision Healthcare, removing a major global distribution channel.
Ongoing operational losses ($5 million net loss in FY 2025) and risk of future share dilution to fund working capital.
Geopolitical and economic instability in Israel, where the company's headquarters and primary operations are located.

Thesis Invalidation Triggers

Failure to secure meaningful commercial contracts or recurring revenue in the U.S. market within the next 12 months.
Rapid depletion of cash reserves leading to an unexpected, highly dilutive equity offering.
Regulatory setbacks or safety concerns raised during the clinical rollout of the Pulsenmore ES system.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.